News and Trends 13 Sep 2022 Results of phase 3 trial of injection for ovarian cancer imaging published An injection for intraoperative imaging of folate receptor positive ovarian cancer can identify more of the disease than is unable to be identified conventionally. Biotech company On Target Laboratories announced that the results from its phase 3, 006 study of the Cytalux (pafolacianine) injection had been published in the Journal of Clinical Oncology yesterday (September […] September 13, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2022 WhiteLab Genomics raises $10M for AI-powered genomic therapies platform WhiteLab Genomics has announced the completion of a $10 million funding round. The round was led by French venture capital firm Omnes Capital, and Debiopharm, a Switzerland based biopharmaceutical company with a venture arm focused on digital health. WhiteLab Genomics said it aims to “revolutionize genomic therapy development” using public and private data and in-house […] September 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2022 New predictive biomarkers to be developed for larynx and hypopharynx carcinomas A study to develop new, potential precision therapies in larynx and hypopharynx carcinomas has been announced today (September 13) by One Biosciences. The company was co-founded by Céline Vallot, Institut Curie and Home Biosciences, combining artificial intelligence (AI) and single-cell technologies to discover new therapeutic targets and develop novel precision medicines. The LARYCARE study, for […] September 13, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2022 Faron Pharmaceuticals’ Traumakine data shows promise for military applications Faron Pharmaceuticals Ltd presented data from its preclinical salvage, preservation, and advanced resuscitation through endothelial stabilization (SPARES) study at the Military Health System Research Symposium (MHSRS) in Orlando, Florida, this week. The data was featured in the “Multi-Organ Dysfunction in Prolonged Field Care Scenarios” breakout session. The SPARES study was a preclinical study, conducted on […] September 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2022 Ilya Pharma partners with US Defense Department for wound healing drug A drug to accelerate wound healing and reduced scar volume has had a major breakthrough shown in results from a first in human trial. Ilya Pharma, a clinical stage immunotherapy company presented the findings at the US Defense Department’s (DoD) Military Health System Research Symposium (MHSRS) Conference in Florida and made the announcement yesterday (September […] September 13, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2022 Arpeggio Biosciences raises $17M in Series A funding to support drug pipeline Arpeggio Biosciences has raised $17 million in series A funding in a round led by Builders VC. Support for the U.S.-based preclinical therapeutics company making technology targeting transcriptional dysregulation in disease, also came from its seed round investors. These include Khosla Ventures, TechU Ventures, FundersClub, Alice Zhang, and Fifty Years, as well as new participants […] September 13, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2022 Starpharma announces new data for prostate cancer trial Cabazitaxel (Jevtana, Sanofi) is a chemotherapy for the treatment of advanced prostate cancer (mCRPC). Developed by Australian biotech company Starpharma, DEP cabazitaxel is a patented, highly water soluble dendrimer nanoparticle version of standard cabazitaxel that has shown, in preclinical and clinical studies, benefits in terms of safety and efficacy. In a poster presentation at ESMO […] September 13, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 13 Sep 2022 Research charity calls on scientists, engineers, and technology experts to transform dialysis treatment Following its successful MedTech competition earlier this year, the UK’s largest kidney research charity, Kidney Research UK, has launched a new competition aimed at innovations in dialysis that will have a significant impact on patients’ lives. In collaboration with IN-PART’s Discover platform, this year’s competition will encourage scientists, academics, engineers and technology experts to propose […] September 13, 2022 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2022 Himalaya Therapeutics publishes data on cancer treatment Himalaya Therapeutics has given an interim topline data update from its phase 2 study of HTBA3011 (mecbotamab vedotin) in non-small cell lung cancer (NSCLC) and certain sarcomas. In August, Himalaya’s collaboration partner, BioAtla publicly announced operational updates on the ongoing global clinical trials for HTBA3011 in patients with AXL-positive NSCLC who have previously failed PD-1/L1, […] September 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2022 Aldatu gets grant to develop Crimean Congo hemorrhagic fever test U.S. biotech company Aldatu Biosciences has been awarded a $3 million Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). The award will fund the advancement of the company’s proprietary PANDAA technology platform and its specific application to the […] September 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2022 Scope Biosciences and WUR to improve CRISPR-Cas technology with new funds Wageningen University & Research (WUR), and its spinoff Scope Biosciences, have received a grant of €150,000 ($152,000) from the European Research Council (ERC). The grant is to further research and enhance the diagnostic technology ScopeDx. This is based on CRISPR-Cas technology. Uniquely, this technology is able to quickly and accurately recognize viral or bacterial RNA. […] September 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 PDC*line Pharma presents results from phase I/II trial PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, has revealed the first results of its PDC-LUNG-101 phase I/II clinical trial with PDC*lung01. PDC*lung01 is the company’s therapeutic off-the shelf cancer vaccine candidate for non-small cell lung cancer (NSCLC). The preliminary data was presented at […] September 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email